NCT04668170View on ClinicalTrials.gov

Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management

CompletedOBSERVATIONAL
Enrollment

304

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

May 2, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Blood collection on admission and longitudinally

Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)

BIOLOGICAL

Blood collection on their first consultation and 10 to 14 days later

Samples already collected on consultation (D0) and 14 days later

Trial Locations (2)

31059

University Hospital Toulouse, Toulouse

33000

University Hospital Bordeaux, Bordeau

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT04668170 - Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management | Biotech Hunter | Biotech Hunter